Core Insights - Cidara Therapeutics is focused on developing innovative anti-infective therapies, particularly through its Cloudbreak® platform for drug-Fc conjugates aimed at serious infections [1] - The company has received an optimistic price target of $153 from JMP Securities, indicating a potential increase of 73.23% from its current trading price [2][6] - Cidara's Phase 3 trial for CD388, a non-vaccine treatment for seasonal influenza, has been accelerated to start in fall 2025 following a positive meeting with the FDA [3][6] Company Developments - The Phase 3 trial for CD388 will now include a broader population, targeting adults over 65, individuals with high-risk co-morbidities, and those with compromised immune systems, which may enhance the drug's market appeal [4][6] - As of the latest update, Cidara's stock is priced at $88.58, reflecting a 20.53% increase, with a market capitalization of $2.25 billion [5]